Table 2.
Cumulative incidence of a rectosigmoid mucosal change (RMC) score ≥ 3 and late rectal complication (LRC) grade ≥ 2 in relation to various dose-volumetric parameters receiving three different dose subgroups
| Parameters | Incidence*of ≥ score 3 RMC | †p-value | Incidence*of ≥ grade 2 LRC | †p-value | |
|---|---|---|---|---|---|
| DRP (Gy3) |
< 65 |
8/25 (32.0) |
0.260 |
7/25 (28.0) |
0.070 |
| |
65–74.9 |
7/27 (25.9) |
|
4/27 (14.8) |
|
| |
≥ 75 |
12/25 (48.0) |
|
11/25(44.0) |
|
| D0.1cc (Gy3) |
< 80 |
4/19 (21.1) |
0.046 |
2/19 (10.5) |
0.066 |
| |
80–94.9 |
9/32 (28.1) |
|
9/32 (28.1) |
|
| |
≥ 95 |
14/26 (53.9) |
|
11/26 (42.3) |
|
| D1cc (Gy3) |
< 75 |
8/36 (22.2) |
0.021 |
6/36 (16.7) |
0.021 |
| |
75–89.9 |
10/27 (37.0) |
|
8/27 (29.6) |
|
| |
≥ 90 |
9/14 (64.3) |
|
8/14 (57.1) |
|
| D2cc (Gy3) |
< 70 |
5/30 (16.7) |
0.010 |
4/30 (13.3) |
0.041 |
| |
70–84.9 |
10/26 (38.5) |
|
9/26 (34.6) |
|
| |
≥ 85 |
12/21 (57.1) |
|
9/21 (42.9) |
|
| D5cc (Gy3) |
< 65 |
4/31(12.9) |
0.002 |
3/31 (9.7) |
0.002 |
| |
65–74.9 |
13/30 (43.3) |
|
10/30 (33.3) |
|
| |
≥ 75 |
10/16 (62.5) |
|
9/16 (56.3) |
|
| D10cc (Gy3) |
< 60 |
6/32 (18.8) |
0.017 |
5/32 (15.6) |
0.082 |
| |
60–64.9 |
10/26 (38.5) |
|
9/26 (34.6) |
|
| |
≥ 65 |
11/19 (57.9) |
|
8/19 (42.1) |
|
| D15cc (Gy3) |
< 55 |
4/28 (14.3) |
0.006 |
4/28 (14.3) |
0.036 |
| |
55–59.9 |
6/17 (35.3) |
|
4/17 (23.5) |
|
| |
≥ 60 |
17/32 (53.1) |
|
14/32 (43.8) |
|
| D20cc (Gy3) |
< 55 |
5/30 (16.7) |
0.011 |
5/30 (16.7) |
0.092 |
| |
55–59.9 |
8/22 (36.4) |
|
6/22 (27.3) |
|
| ≥ 60 | 14/25 (56.0) | 11/25 (44.0) |
Abbreviations: same as in Table 2.
*Cumulative incidence = number of patients who developed an RMC score ≥ 3 or LRC grade ≥ 2 / number of patients at risk (%) during follow-up.
†Fisher’s exact test.